Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting
[1]. DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89(4):515-527.
















